EyePoint Pharmaceuticals (STU:PV3B) 5-Year ROIIC %

: 155.96% (As of Dec. 2022)

View and export this data going back to 2009. Start your Free Trial

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. EyePoint Pharmaceuticals does not have enough data to calculate 5-Year ROIIC %.

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

EyePoint Pharmaceuticals 5-Year ROIIC % Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's 5-Year ROIIC % falls in comparison to its industry or sector. The grey bar indicates the 5-Year ROIIC %'s extreme value range as defined by GuruFocus.

EyePoint Pharmaceuticals 5-Year ROIIC % Calculation

EyePoint Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

5-Year ROIIC %	=	5-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	5-Year Incremental Invested Capital^**
	=	( -74.517471999881 (Dec. 2022) - (Dec. 2017) )	/	( 18.69780799997 (Dec. 2022) - (Dec. 2017) )
	=		/
	=	N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

^**Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.

EyePoint Pharmaceuticals (STU:PV3B) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

EyePoint Pharmaceuticals 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » 5-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines